A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS

Trial Profile

A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Aspirin; Cyclophosphamide; Dexamethasone; Enoxaparin sodium; Granulocyte colony-stimulating factors; Melphalan; Prednisone
  • Indications Deep vein thrombosis; Multiple myeloma; Myocardial infarction; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms MPRvsMEL200
  • Most Recent Events

    • 03 Jun 2016 According to a Celgene Corporation media release, Pooled data from meta-analysis (n=1209) from this and other two phase III studies (see profiles 21477, 1712) were presented at the 52nd ASCO Annual Meeting.
    • 03 Jun 2016 Pooled data from meta-analysis (n=1209) from this and other two phase III studies (see profiles 21477, 1712) published in a Celgene Corporation media release.
    • 04 Sep 2014 Status changed from active, no longer recruiting to completed according to results published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top